Quick Takeaways
- MORGAN STANLEY filed SCHEDULE 13G/A for UroGen Pharma Ltd. Ordinary Shares (URGN).
- Disclosed ownership: 1.8%.
- Date of event: 31 Dec 2024.
MORGAN STANLEY - 31 Dec 2024 SCHEDULE 13G/A Report for UroGen Pharma Ltd. Ordinary Shares (URGN)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Security
- UroGen Pharma Ltd. Ordinary Shares
- Symbol
- URGN
- Shares outstanding
- 41,825,611 shares
- Disclosed Ownership
- 752,861 shares
- Ownership
- 1.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 05 Feb 2025, 10:09:20 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 06 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MORGAN STANLEY disclosed 1.8% ownership in UroGen Pharma Ltd. Ordinary Shares (URGN) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 05 Feb 2025, 10:09.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 1.8% | 752,861 | 0 | 748,211 | Christopher O'Hara | Authorized Signatory, Morgan Stanley |